Cereno Scientific has been cleared to launch a Phase 1 clinical trial in Sweden to evaluate the pharmacological properties of CS014, its experimental oral treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The upcoming study in healthy volunteers was designed based on feedback from the U.S.
Discussion
Unless you’ve been hiding under a rock lately, you’ve probably noticed how astronomical the cost of living has become. I’m talking about the basics: keeping a roof over our heads and food on the table, and securing the everyday necessities we all need to get through the day. Honestly,…
Scientists in China have uncovered key genetic drivers of the abnormal thickening of lung blood vessels that is a hallmark of idiopathic pulmonary arterial hypertension (IPAH), where the cause is unknown. By mapping individual lung cells and applying advanced tools, scientists identified two genes — POSTN and CCDC80…
Discussion
I recently went to Washington, D.C., as part of the Pulmonary Hypertension Association’s (PHA) Capitol Hill Day to advocate for the pulmonary hypertension (PH) community and help secure co-sponsorship of the Supplemental Oxygen Access Reform Act (SOAR) and the Safe Step Act. The SOAR Act seeks to reform…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
